<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02673970</url>
  </required_header>
  <id_info>
    <org_study_id>2014-BN-001</org_study_id>
    <nct_id>NCT02673970</nct_id>
  </id_info>
  <brief_title>Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma</brief_title>
  <acronym>ICIT</acronym>
  <official_title>Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Screen and recruitment: patients will be screened based on their prior history and
           intention to initiate treatment with an immune checkpoint inhibitor.

        2. Study phase:

             -  Collection of baseline demographic data, prior disease history, nature of ICI
                therapy, outcome data of ICI therapy (treatment disposition, toxicity, tumor
                response and survival).

             -  Collection of blood samples will be performed every 3 to 4 weeks for the first year
                on ICI therapy and every 6 to 12 weeks thereafter until the end of ICI therapy,
                disease progression, death or loss to follow-up. Collection of blood samples will
                be aligned with the visits necessary for the administration of the ICI therapy.

             -  Collection of archival melanoma metastasis tissues will be performed on a
                continuous basis and be triggered by availability of such tissue following
                therapeutic resections of melanoma metastases.

        3. Follow-up phase
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Screen and recruitment: patients will be screened based on their prior history and
           intention to initiate treatment with an immune checkpoint inhibitor. This screening of
           candidate patients by the investigators will be non-interventional. Patients that are
           considered eligible candidates will be invited to participate in this study and to Page
           3/18 provide written informed consent.

        2. Study phase:

             -  Collection of baseline demographic data, prior disease history, nature of ICI
                therapy, outcome data of ICI therapy (treatment disposition, toxicity, tumor
                response and survival).

             -  Collection of blood samples will be performed every 3 to 4 weeks for the first year
                on ICI therapy and every 6 to 12 weeks thereafter until the end of ICI therapy,
                disease progression, death or loss to follow-up. Collection of blood samples will
                be aligned with the visits necessary for the administration of the ICI therapy.

             -  Collection of archival melanoma metastasis tissues will be performed on a
                continuous basis and be triggered by availability of such tissue following
                therapeutic resections of melanoma metastases.

        3. Follow-up phase: patients who stop treatment with the immune checkpoint inhibitor will
           be followed-up for
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>explore the value of biomarkers present in blood, and tumor tissue for the purpose of predicting the efficacy of ICI therapy or for the purpose of monitoring the therapeutic effect of ICI therapy</measure>
    <time_frame>1year</time_frame>
    <description>explore the value of biomarkers present in blood, and tumor tissue for the purpose of predicting the efficacy of ICI therapy or for the purpose of monitoring the therapeutic effect of ICI therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline demographic data, prior disease history, nature of ICI therapy, treatment disposition, adverse events</measure>
    <time_frame>1year</time_frame>
    <description>Baseline demographic data, prior disease history, nature of ICI therapy, treatment disposition, adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response according to the RECISTv1.1 and irRC criteria</measure>
    <time_frame>1 year</time_frame>
    <description>Tumor response according to the RECISTv1.1 and irRC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival (PFS, and OS) by Kaplan-Meier estimates</measure>
    <time_frame>1year</time_frame>
    <description>Survival (PFS, and OS) by Kaplan-Meier estimates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Data collection on the nature and disposition of ICI therapy as well as its efficacy and treatment related adverse events will be collected on a non-interventional basis</measure>
    <time_frame>1 year</time_frame>
    <description>Data collection on the nature and disposition of ICI therapy as well as its efficacy and treatment related adverse events will be collected on a non-interventional basis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>observational arm</arm_group_label>
    <description>From start treatment till date of death or date of cure, the patient will be followed for survival and adverse events on pembrolizumab</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cllection of cell free DNA for mutational analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patient with an unresectable stage III or stage IV melanoma treated with pembrolizumab
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed malignant melanoma;

          2. AJCC Stage IIIC or IV melanoma with evaluable disease;

          3. Treatment with an immune checkpoint inhibitor;

          4. Willing and able to give written informed consent;

          5. Accessible for treatment and follow-up;

        Exclusion Criteria:

          -  non
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart NEyns, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bart Neyns, MD; PhD</last_name>
    <phone>024746040</phone>
    <email>bart.neyns@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yanina Jansen, MD</last_name>
    <phone>024746040</phone>
    <email>yanina.jansen@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Jette</city>
        <state>Brabant</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Neyns, Phd,Md</last_name>
      <phone>0032(0)2477 64 15</phone>
      <email>bart.neyns@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Bart Neyns, Phd,Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Laken</city>
        <state>Brussels</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrien Vandenbossche, study nurse</last_name>
      <phone>0032 2 477 54 47</phone>
      <email>katrien.vandenbossche@uzbrussel.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <results_reference>
    <citation>Wilgenhof S, Du Four S, Vandenbroucke F, Everaert H, Salmon I, Li√©nard D, Marmol VD, Neyns B. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother. 2013 Apr;36(3):215-22. doi: 10.1097/CJI.0b013e31828eed39.</citation>
    <PMID>23502769</PMID>
  </results_reference>
  <results_reference>
    <citation>Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10;31(5):616-22. doi: 10.1200/JCO.2012.44.6112. Epub 2013 Jan 7.</citation>
    <PMID>23295794</PMID>
  </results_reference>
  <results_reference>
    <citation>Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013 Dec 1;31(34):4311-8. doi: 10.1200/JCO.2013.51.4802. Epub 2013 Oct 21.</citation>
    <PMID>24145345</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <last_update_submitted>September 8, 2016</last_update_submitted>
  <last_update_submitted_qc>September 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Bart Neyns</investigator_full_name>
    <investigator_title>PhD MD Bart Neyns</investigator_title>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

